Skip to content
← Full study record

NCT03258554 · OUTCOME

Change in the EORTC QLQ C30 Global Heath Status Score at One Year

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin · Source last updated 2026-08-27

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline and one year

What was measured

The EORTC QLQ C30 Global Heath Status score measures overall health related quality of life. Possible scores for each scale range from 0 to 100, with higher scores indicate better overall quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement for and negative values indicate.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The EORTC QLQ C30 Global Heath Status score measures overall health related quality of life. Possible scores for each scale range from 0 to 100, with higher scores indicate better overall quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement for and negative values indicate.
reporting Status
NOT_POSTED
time Frame
Baseline and one year
title
Change in the EORTC QLQ C30 Global Heath Status Score at One Year
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice